Pfizer COVID vaccine trial for children aged under 12 shows 'robust immune response'

Credit: Sky News- Published on September 20, 2021
A Pfizer-BioNTech COVID-19 vaccine trial for children aged between five and 11 has produced "positive results" and has shown a "robust immune response", the two firms have said.

Video credit: Wibbitz Top Stories
Published on September 20, 2021 -  01:30
Pfizer Says Trial Shows COVID-19 Vaccine Is Safe and Effective for 5 to 11 Year-Olds
Pfizer Says Trial Shows, COVID-19 Vaccine , Is Safe and Effective for 5 to 11 Year-Olds. On September 20, Pfizer said that a Phase 2/3 trial showed that its COVID-19 vaccine was safe and effective for children ages 5 to 11. CNN reports that these are the first such results released for this age group for a COVID-19 vaccine in the United States. CNN also points out that the data from the study has not yet been peer-reviewed or published. CNN also points out that the data from the study has not yet been peer-reviewed or published. According to the FDA, once the Pfizer data is submitted, the agency could authorize a vaccine for younger children in a matter of weeks. According to the FDA, once the Pfizer data is submitted, the agency could authorize a vaccine for younger children in a matter of weeks. The trial, which included 2,268 participants ages 5 to 11, used a two-dose regimen of the vaccine administered 21 days apart. The trial, which included 2,268 participants ages 5 to 11, used a two-dose regimen of the vaccine administered 21 days apart. A 10-microgram dose, smaller than the 30-microgram dose that has been used for those 12 and older, was administered in the trial. A 10-microgram dose, smaller than the 30-microgram dose that has been used for those 12 and older, was administered in the trial. The 10 microgram dose was carefully selected as the preferred dose for safety, tolerability and immunogenicity in children 5 to 11 years of age, Pfizer news release, via CNN. The 10 microgram dose was carefully selected as the preferred dose for safety, tolerability and immunogenicity in children 5 to 11 years of age, Pfizer news release, via CNN. Pfizer said the levels compared well with older people who received the larger dose, demonstrating a , "strong immune response in this cohort of children one month after the second dose.". Further, the COVID-19 vaccine was well tolerated, with side effects generally comparable to those observed in participants 16 to 25 years of age, Pfizer news release, via CNN. According to a spokesperson for Pfizer, the trial resulted in no instances of myocarditis, ... ... a type of heart inflammation that has been linked with mRNA vaccines

You are here


💡 newsR Knowledge: Other News Mentions

COVID-19

Contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Over 102 crore Covid-19 vaccine doses have so far been administered in the country, including more than 70 lakh doses administered on Saturday, the Union health..
Credit: IndiaTimes - Published 24 minutes ago

Chairman and Managing Director of Bharat Biotech, Dr. Krishna Ella on Saturday said that they are waiting for approval from the Drugs Controller General of India..
Credit: IndiaTimes - Published 1 hour ago

Representatives from India's leading Covid vaccine manufacturers lauded PM Modi for his encouragement in research and innovation. They appreciated PM's..
Credit: IndiaTimes - Published 3 hours ago



BioNTech

German biotechnology company

Related videos from verified sources

Pfizer Says Its Vaccine Is Over 90% Effective Against COVID-19 in Children 5 to 11 01:30
Credit: Wibbitz Top Stories - Published 23 hours ago 


State prepares to administer COVID-19 vaccine to children 01:03
Credit: WCVB - Published 1 day ago 


Valley parents signing up children for COVID-19 vaccine 01:42
Credit: ABC15 Arizona - Published 2 days ago 


You might like